Therapeutic Drug Monitoring (TDM) with different tolerable doses of memantine for cognitive function preservation in Indian patients with brain metastasis treated with radiation. - NIL

Start Date01 May 2025

Sponsor / Collaborator-

ACTRN12624001274561 / Not yet recruitingPhase 1

A Phase 1 Open-label Skin Safety, Tolerability and Pharmacokinetic Study of MRX-7MLL (Memantine Transdermal Delivery System) in Healthy Adults

Start Date27 Nov 2024

Sponsor / Collaborator-

NCT06679387 / RecruitingPhase 2IIT

"The Effect of Memantine on the Prevention and Amelioration of Paclitaxel-induced Toxicity in Breast Cancer Patients"

Cancer is currently a leading cause of morbidity and mortality worldwide. Chemotherapeutic agents, despite being effective in arresting the progression of cancer by targeting and eliminating rapidly dividing cancer cells, are associated with various adverse effects. Chemotherapy-induced peripheral neuropathy (CIPN) is a serious clinical adverse effect of certain chemotherapeutic agents. For many patients, CIPN symptoms could be severe, disabling, and significantly impairing the activities of daily living (ADL) and diminishing the quality of life (QoL). Paclitaxel-induced peripheral neuropathy may affect up to 97% of paclitaxel-treated patients and become chronic in more than 60% of cases. The initial symptoms of paclitaxel-induced peripheral neuropathy (PIPN) include numbness, tingling, and allodynia (painful sensations in response to normally non-painful stimuli) that can be manifested in the patient's fingers and toes within 24-72 h post-injection. These symptoms may later progress to affect the patient's lower leg and wrists in a "glove and stocking" pattern. Symptoms typically begin distally and continue proximally as the situation worsens. Memantine is a non-competitive NMDA receptor antagonist that inhibits the prolonged influx of Ca2+, responsible for neuronal excitotoxicity while maintaining the physiological NMDA receptor's function and avoiding psychotropic adverse events. Although memantine has been the main treatment option for moderate and severe Alzheimer's disease in the last two decades, numerous studies have investigated its other potential uses. Some studies showed that memantine diminished chronic pain in complex regional pain syndrome, phantom limb pain, and fibromyalgia. Most in vivo and in vitro studies attributed the neuroprotective effects of memantine to the blockade of NMDA receptors on neurons as well as inhibition of microglia activation with subsequent reduction of pro-inflammatory mediators' production such as extracellular superoxide anion, intracellular ROS, nitric oxide, prostaglandin E2, and TNF-α, and stimulation of neurotrophic factor release from astroglia.

Start Date30 Oct 2024

Sponsor / Collaborator

Ain Shams University

100 Clinical Results associated with Memantine hydrochloride

100 Translational Medicine associated with Memantine hydrochloride

100 Patents (Medical) associated with Memantine hydrochloride

207

Literatures (Medical) associated with Memantine hydrochloride

01 Feb 2025·Pharmaceutical Nanotechnology

Optimizing Neuroprotective Nano-structured Lipid Carriers for Transdermal Delivery through Artificial Neural Network

Article

Author: Dalwadi, Saloni ; Prajapati, Bhupendra ; Thakkar, Vaishali

Background:Dementia associated with Alzheimer’s disease (AD) is a neurological disorder. AD is a progressive neurodegenerative condition that predominantly impacts the elderly population, although it can also manifest in younger people through the impairment of cognitive functions, such as memory, cognition, and behaviour. Donepezil HCl and Memantine HCl are encapsulated in Nanostructured Lipid Carriers (NLCs) to prolong systemic circulation and minimize the systemic side effects.Objective:This work explores the use of data mining tools to optimize the formulation of NLCs comprising of Donepezil HCl and Memantine HCl for transdermal drug delivery. Neuroprotective drugs and excipients are utilized for protecting the nervous system against damage or degeneration.Methods:The NLCs were formulated using a high-speed homogenization technique followed by ultrasonication. NLCs were optimized using Box Behnken Design (BBD) in Design Expert Software and artificial neural network (ANN) in IBM SPSS statistics. The independent variables included the ratio of solid lipid to liquid lipid, the percentage of surfactant, and the revolutions per minute (RPM) of the high-speed homogenizer.Results:The NLCs that were formulated had a mean particle size ranging from 67.0±0.45 to 142.4±0.52 nm. Both drugs have a %EE range over 75%, and Zeta potential was determined to be - 26±0.36 mV. CryoSEM was used to do the structural study. The permeation study showed the prolonged release of the formulation.Conclusion:The results indicate that NLCs have the potential to be a carrier for transporting medications to deeper layers of the skin and reaching systemic circulation, making them a suitable formulation for the management of Dementia. Both ANN and BBD techniques are effective tools for systematically developing and optimizing NLC formulation.

01 Aug 2024·Biomedicine & Pharmacotherapy

Mitigating radiation-induced brain injury via NLRP3/NLRC4/Caspase-1 pyroptosis pathway: Efficacy of memantine and hydrogen-rich water

Article

Author: Wang, Yong ; Sun, Ge ; Wang, Yuhao ; Lu, Xiaoyu ; Qin, Xiujun ; Luo, Hao ; Liu, Huan ; Liu, Mengya ; Xu, Kai

Radiation-induced brain injury (RIBI) is a significant challenge in radiotherapy for head and neck tumors, impacting patients' quality of life. In exploring potential treatments, this study focuses on memantine hydrochloride and hydrogen-rich water, hypothesized to mitigate RIBI through inhibiting the NLRP3/NLRC4/Caspase-1 pathway. In a controlled study involving 40 Sprague-Dawley rats, divided into five groups including a control and various treatment groups, we assessed the effects of these treatments on RIBI. Post-irradiation, all irradiated groups displayed symptoms like weight loss and salivation, with notable variations among different treatment approaches. Particularly, hydrogen-rich water showed a promising reduction in these symptoms. Histopathological analysis indicated substantial hippocampal damage in the radiation-only group, while the groups receiving memantine and/or hydrogen-rich water exhibited significant mitigation of such damage. Molecular studies, revealed a decrease in oxidative stress markers and an attenuated inflammatory response in the treatment groups. Immunohistochemistry further confirmed these molecular changes, suggesting the effectiveness of these agents. Echoing recent scientific inquiries into the protective roles of specific compounds against radiation-induced damages, our study adds to the growing body of evidence on the potential of memantine and hydrogen-rich water as novel therapeutic strategies for RIBI.

01 Feb 2024·Analytical Science Advances

Screening stabilisers for cyanoenone triterpenoid TX101 in rat plasma samples by simultaneous analysis of parent drug and the epoxidation product

Article

Author: Tian, Lynn ; Tamer, Edward ; Tian, Qingguo

AbstractIn the development of bioanalytical methods, stabilizing drug molecules in biological matrices is crucial for ensuring reliable exposure data in pharmacokinetic and toxicokinetic sample analyses. This study focuses on the evaluation of stabilizing effects on the synthetic triterpenoid TX101, a cyanoenone triterpenoid Nrf2 activator with known instability in plasma samples. The molecule's unsaturated double bond is susceptible to oxidation, either nonenzymatically via oxygen or enzymatically through cytochrome P450 enzyme‐catalyzed epoxidation. The research explores the impact of antioxidants (L‐ascorbic acid, sodium metabisulfite, sodium sulfite) and P450 enzyme inhibitors (sodium diethyldithiocarbamate, memantine hydrochloride, 1‐aminobenzotriazole) on TX101 stability in rat plasma samples. Results reveal that adding 2.5 mg/mL sodium sulfite or sodium metabisulfite effectively inhibits the nonenzymatic oxidation of TX101 to TX101‐epoxide, while L‐ascorbic acid shows minimal stabilizing effect. Among P450 enzyme inhibitors, sodium diethyldithiocarbamate and memantine hydrochloride exhibit modest stabilizing effects, likely attributed to their antioxidant activity. The developed High‐formance liquid chromatography coupled to tandem mass spectrometry (LC–MS/MS) method, incorporating Supported Liquid Extraction for sample cleanup, allows simultaneous monitoring of TX101 and TX101‐epoxide. Application of this method in a rat dose‐range finding study confirms successful inhibition of TX101‐epoxide formation in samples treated with sodium sulfite or sodium metabisulfite. Overall, the study emphasizes the importance of stabilizers in preventing nonenzymatic oxidation reactions during sample storage, providing valuable insights for bioanalytical method development and validation.

News (Medical) associated with Memantine hydrochloride

12 Nov 2024

·www.businesswire.com

Alpha Cognition Announces Pricing of $50 Million Upsized Public Offering and Nasdaq Listing

VANCOUVER, British Columbia--( BUSINESS WIRE )--Alpha Cognition Inc. (Nasdaq: ACOG) (CSE: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the pricing of its upsized public offering of 8,695,653 common shares at a public offering price of $5.75 per share, for gross proceeds of approximately $50 million, before deducting underwriting discounts, commissions, and estimated offering expenses. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 1,184,592 common shares to cover over-allotments at the public offering price, less the underwriting discount. All of the common shares are being offered by the Company. The offering is expected to close on November 13, 2024, subject to the satisfaction of customary closing conditions. The Company has received approval to list its common shares on the Nasdaq Capital Market under the symbol “ACOG” and is expected to begin trading on Nasdaq today, November 12, 2024. The Company intends to use the proceeds towards the commercialization and launch of ZUNVEYL TM in Alzheimer’s Disease, further research and development of its pipeline product candidates, continued commercial CMC activities (chemistry, manufacturing, and controls), and for working capital and general corporate purposes. “This offering serves as a tremendous milestone for Alpha Cognition, as we begin the commercialization of our FDA-approved drug, ZUNVEYL, for the treatment of mild-to-moderate Alzheimer’s Disease,” said Michael McFadden, Chief Executive Officer and Director of the Company. "This financing puts our balance sheet in a position of meaningful strength and provides the necessary foundation for a successful commercial launch, with ample runway to scale over the next few years. We are thrilled to welcome a number of new, high-quality investors to our Nasdaq listing, who also see the benefits of ZUNVEYL and the exciting opportunity for our platform.” Titan Partners Group, a division of American Capital Partners, is acting as Sole Bookrunner for the offering. The securities were sold pursuant to a registration statement on Form S-1 (File No. 333-280196) relating to these securities and a related registration statement on Form S-1 MEF that became effective upon its filing in accordance with Rule 462(b) under the Securities Act of 1933, as amended. The Offering is being made only by means of a prospectus. A copy of the final prospectus related to the Offering may be obtained, when available, from Titan Partners Group LLC, a division of American Capital Partners, LLC, 4 World Trade Center, 29th Floor, New York, NY 10007, or via email at prospectus@titanpartnersgrp.com or telephone at (929) 833-1246. In addition, a copy of the final prospectus, when available, relating to the Offering may be obtained via the SEC's website at www.sec.gov . This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Alpha Cognition Inc. Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (“mTBI”), for which there are currently no approved treatment options. ZUNVEYL is a patented drug approved as a new generation acetylcholinesterase inhibitor (AChEI) for the treatment of Alzheimer’s disease, with expected minimal gastrointestinal side effects. ZUNVEYL’s active metabolite is differentiated from donepezil and rivastigmine in that it improves the function of neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. Benzgalantamine is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. Forward-looking Statements This news release includes forward-looking statements within the meaning of applicable securities laws. Except for statements of historical fact, any information contained in this news release may be a forward‐looking statement that reflects the Company’s current views about future events and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward‐looking statements by the words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “target,” “seek,” “contemplate,” “continue” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward‐looking statements may include statements regarding the potential closing of the Offering, the use of proceeds of the Offering, receipt of regulatory and stock exchange approvals in connection with Offering and completion of the Nasdaq uplisting. Although the Company believes to have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. The Company cannot assure that the actual results will be consistent with these forward-looking statements. These forward‐looking statements speak only as of the date of this news release and the Company undertakes no obligation to revise or update any forward‐looking statements for any reason, even if new information becomes available in the future.

Drug ApprovalClinical Study

28 Aug 2024

·www.drugs.com

Cholinesterase Inhibitors Beneficial for Dementia With Lewy Bodies

WEDNESDAY, Aug. 28, 2024 -- Cholinesterase inhibitors (ChEIs) are beneficial for patients with dementia with Lewy bodies (DLB), according to a study published online Aug. 23 in Alzheimer's & Dementia . Hong Xu, M.D., Ph.D., from the Center for Alzheimer Research at the Karolinska Institutet in Stockholm, and colleagues examined the impact of ChEIs and memantine on cognition, major adverse cardiovascular events, and mortality in patients with DLB. Data were included from 1,095 incident DLB patients. The effect of initiating a ChEI or memantine within 90 days of DLB diagnosis and nonuse was assessed. The researchers found that compared with memantine and nonuse, use of ChEIs significantly slowed cognitive decline at follow-ups (Mini-Mental State Examination, −0.39 points per year versus −2.49 and −2.50 points per year, respectively). No difference in major adverse cardiovascular events was seen for the treatment groups. There was an association observed for ChEI use with a lower risk for death in the first year after DLB diagnosis (adjusted hazard ratio, 0.66). "Future studies are needed to better elucidate these mechanisms," the authors write. "Clinical trials should be conducted for longer than two years of follow-up to assess long-term outcomes such as cardiovascular events and mortality." Abstract/Full Text Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

AHA

13 Aug 2024

·www.businesswire.com

Alpha Cognition, Inc. On Track to Secure Financing for Continued Growth

VANCOUVER, British Columbia & DALLAS--( BUSINESS WIRE )-- Alpha Cognition (CSE: ACOG) (OTCQB: ACOGF) (Alpha Cognition “ACI”, or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, announced today its decision to temporarily delay its planned capital raise and uplisting to the NASDAQ Capital Market due to current challenging market conditions. The management team at Alpha Cognition has determined that the proposed terms associated with the capital raise needed for its uplisting to Nasdaq were not best aligned with the company's current goal of pursuing commercialization of ZUNVEYL in a manner consistent with the best interests of its current shareholders. As such, the Company has chosen to explore alternative strategies that better protect shareholder value while continuing to advance its strategic objectives. “While this is not our desired outcome, current market conditions have been most challenging, and Alpha Cognition’s strategic objectives must align with our duty to implement our business plans in the best interests of our existing shareholders,” said Michael McFadden, CEO of Alpha Cognition, Inc. “Our priority remains focused on executing our business plan, preparing for the commercialization of ZUNVEYL, and exploring alternative equity and non-dilutive funding options.” Alpha Cognition has received indications of interest from parties wanting to provide bridge funding to the Company, which should allow the Company to continue critical activities, including commercial supply manufacturing, advancing pricing work, and preparing for the Q1 2025 launch of ZUNVEYL in the U.S. market. The Company is confident that these bridge funds will enable it to maintain momentum as it considers different strategies for further funding for the advancement of its commercialization efforts, particularly in the largest segment of the Alzheimer’s market. The Company will also continue discussions with potential partners and actively pursue non-dilutive capital options to support its growth objectives without compromising shareholder value. Alpha Cognition remains steadfast in its commitment to developing innovative treatments for patients suffering from neurodegenerative diseases and looks forward to providing further updates as it progresses towards its strategic goals. About Alpha Cognition Inc. Alpha Cognition Inc. is a commercial development stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease (“AD”) and Cognitive Impairment with mild Traumatic Brain Injury (“mTBI”), for which there are currently no approved treatment options. ZUNVEYL, previously ALPHA-1062, is a novel patented oral AD therapy with a dual mechanism of action designed to eliminate drug absorption in the GI tract, potentially addressing certain tolerability issues with leading AD medications, combined with the efficacy and long-term benefit profile of galantamine. As a new generation acetylcholinesterase inhibitor, it was developed to demonstrate a potentially improved GI side effect profile and has a CNS safety profile that includes no incidence of insomnia. While precise mechanism of action is not known, it is believed that ZUNVEYL works through two distinct pathways to enhance neurotransmitter activity and protect neuronal health, leading to improved cognitive and functional outcomes. Separately, ZUNVEYL is also being developed in combination with memantine to treat moderate-to-severe AD, and as an intranasal formulation for Cognitive Impairment with mTBI. For more information about ZUNVEYL, please visit www.zunveyl.com or contact info@alphacognition.com and connect with us on Twitter and LinkedIn . Forward-looking Statements This news release includes forward-looking statements within the meaning of applicable United States and Canadian securities laws. Except for statements of historical fact, any information contained in this news release may be a forward‐looking statement that reflects the Company’s current views about future events and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward‐looking statements by the words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “target,” “seek,” “contemplate,” “continue” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward‐looking statements may include statements regarding the Company’s ability to obtain bridge funding in an amount and on terms satisfactory to the Company to continue to implement its business plan, the Company’s potential uses of any bridge funding it does receive, the Company’s ability to adequately implement its business plan upon receipt of bridge funding, the Company’s ability to continue to pursue financings in the future, the Company’s future plans to uplist to Nasdaq, the Company continued conversations with strategic partners, the Company’s ability to obtain alternative and non-dilutive funding, the Company’s business strategy, market size, potential growth opportunities, capital requirements, clinical development activities, the timing and results of clinical trials, regulatory submissions, potential regulatory approval and commercialization of the Company’s products. Although the Company believes to have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. The Company cannot assure that the actual results will be consistent with these forward-looking statements. These forward-looking statements are subject to certain risks, including risks regarding our ability to raise sufficient capital, including bridge funding, to implement our plans to commercialize ZUNVEYL , risks regarding the efficacy and tolerability of ZUNVEYL , risks related to ongoing regulatory oversight on the safety of ZUNVEYL, risk related to market adoption of ZUNVEYL , risks related to the Company’s intellectual property in relation to ZUNVEYL , risks related to the commercial manufacturing, distribution, marketing and sale of ZUNVEYL , risks related to product liability and other risks as described in the Company’s filings with Canadian securities regulatory authorities and available at www.sedar.com and the Company’s filings with the United States Securities and Exchange Commission (the “SEC”), including those risk factors under the heading “Risk Factors” in the Company’s Form S-1 registration statement as filed with the SEC on June 14, 2024 and available at www.sec.gov . These forward‐looking statements speak only as of the date of this news release and the Company undertakes no obligation to revise or update any forward‐looking statements for any reason, even if new information becomes available in the future, except as required by law.

100 Deals associated with Memantine hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D04905	Memantine hydrochloride	N06DX01	DB01043

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Alzheimer Disease	IS	H. Lundbeck A/S	15 May 2002
Alzheimer Disease	NO	H. Lundbeck A/S	15 May 2002
Alzheimer Disease	EU	H. Lundbeck A/S	15 May 2002
Alzheimer Disease	LI	H. Lundbeck A/S	15 May 2002
Dementia	DE	H. Lundbeck A/S	11 Aug 2000

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cognitive Dysfunction	Phase 3	US	Forest Laboratories, Inc.	01 Apr 2004
Multiple Sclerosis	Phase 3	US	Forest Laboratories, Inc.	01 Apr 2004
Alzheimer Disease	Phase 2	US	Allergan Sales LLC	18 Apr 2005
Dementia due to Alzheimer's disease (disorder)	Preclinical	US	Forest Laboratories LLC	01 Jun 2005
Dementia due to Alzheimer's disease (disorder)	Preclinical	CL	Forest Laboratories LLC	01 Jun 2005
Agitation	Preclinical	US	Forest Laboratories LLC	01 Sep 2004
Cognitive Dysfunction	Preclinical	US	Forest Laboratories, Inc.	01 Apr 2004
Multiple Sclerosis	Discovery	US	Forest Laboratories, Inc.	01 Apr 2004
Glaucoma, Open-Angle	Discovery	-	Allergan Ltd. (Ireland)	01 Mar 1999

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04792645 (CTgov)	Phase 2	Trichotillomania \| Skin Diseases	100	Placebo (Placebo)	rpjusjawqt(txqtbxmklq) = olqewzzfpj kxjurhmuyb (orqbijlxft, tqbsgykzyo - feaykizcvx) View more	-	01 Aug 2023
				Memantine (Memantine)	rpjusjawqt(txqtbxmklq) = ybxfdfsdvw kxjurhmuyb (orqbijlxft, fbpzuigkoz - nqaaxakzid) View more
NCT04698525 (CTgov)	Phase 3	Migraine Disorders	33	Valproate Sodium (Valproate Group)	htqnhlftnt(hlorbdsqad) = idfwqsirci vpazcshzos (ketyydysnt, xuiktaqple - iplzoktmbg) View more	-	17 May 2023
				memantine (Memantine)	htqnhlftnt(hlorbdsqad) = kpydifufyf vpazcshzos (ketyydysnt, rguscqdgap - uengltzyqo) View more
NCT02118727 (TAME, CTgov)	Phase 2	Frontotemporal Dementia \| Amyotrophic Lateral Sclerosis	89	Memantine (Memantine)	ctydhxlcmc(bgkdjbqzgy) = qozhpoewze astrtalyqw (heopsgliez, iyxpgxbhgo - mbcskprzqs) View more	-	29 Nov 2022
				Placebo (for Memantine) (Placebo)	ctydhxlcmc(bgkdjbqzgy) = cbgxvavwvf astrtalyqw (heopsgliez, cfgcoolsjg - oczhrutgqn) View more
NCT04033419 (ASCO2022) Manual	Phase 2	Early Stage Breast Carcinoma	56	memantine	(ierwjsczus) = xldahxthjm nafnbrepzk (ivwhkljspw ) View more	Positive	02 Jun 2022
NCT02304302 (CTgov)	Phase 2	Down Syndrome	160	Placebo (Placebo)	voqjwlbldl(iicxvagwma) = bdidzphuza mwuaxvkuni (qtoaahixdk, vthjgmtblq - wiuaudamah) View more	-	05 Apr 2022
				Memantine (Memantine)	voqjwlbldl(iicxvagwma) = njjasgjjcl mwuaxvkuni (qtoaahixdk, akfytobrai - cvachluuvh) View more
NCT02304302 (Pubmed) Manual	Phase 2	Down Syndrome	160	memantine	ywbenylskx(ihkhjjoiri): difference = 0.34 (95% CI, -0.98 to 1.67), P-Value = 0.61 View more	Negative	01 Jan 2022
				Placebo
NCT03988803 (CTgov)	Phase 1	-	16	BI 425809 (BI 425809)	teqzxlbwff(mncjsverhn) = ymkdwohkad jjxrmyywzp (acsqrlveeu, uvbmoirmyb - wjbxvdwvja) View more	-	17 Mar 2021
				Memantine+BI 425809 (Memantine + BI 425809)	teqzxlbwff(mncjsverhn) = cxoqymyyhu jjxrmyywzp (acsqrlveeu, pktigxfwtw - pyqhvcjoai) View more
NCT02535611 (EMISO, CTgov)	Phase 3	Ischemic stroke	47	Memantine (Memantine)	opzkqozrnn(xpunjkxodf) = tafyxvphxt adijagmnlk (ssgntxtimt, yfengbjeqx - slcibxijux) View more	-	16 Sep 2020
				Placebo (Placebo)	opzkqozrnn(xpunjkxodf) = pefskugmno adijagmnlk (ssgntxtimt, gxasffvqlv - zorfchhxos) View more
EAN	Not Applicable	Dementia	30	Memantine + basic therapy	fhprzysadr(ioiomuohje) = memantine effectively affects behavioral disorders hhakpfohap (qvlwwyzcgo ) View more	Positive	22 May 2020
				Basic therapy
NCT02360215 (CTgov)	Phase 3	Cognitive Dysfunction \| Brain metastases	518	Whole brain radiation therapy+memantine	ybmwyrkmcg(wwwtimruzf) = qnuhrgkxds cjtutckvzj (vvyoftzyyd, ucygjvpici - jhxpntosvw) View more	-	06 Mar 2020

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis